Lantheus Holdings presents a mixed fundamental picture: robust cash generation and a strengthening balance sheet contrast with decelerating revenue growth and margin compression. Operating cash flow has consistently exceeded net income, with OCF/NI reaching 2....
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has decelerated sharply from 22.5% in 2024Q2 to 2.7% in 2026Q2, while gross margin compressed from 68.1% to 62.3%, indicating eroding pricing power and rising costs.
Lantheus Holdings is a publicly traded company on NASDAQ, providing liquidity and visibility to investors.
The company owns subsidiaries like Lantheus Medical Imaging, Progenics Pharmaceuticals, and EXINI Diagnostics, diversifying its business operations.
LNTH stock offers real-time price tracking and detailed financial overviews, aiding informed investment decisions.
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.55+19.2% vs $1.30 | $388M+6.9% vs $363M |
Q2 2026 May 7, 2026 | $1.46+16.8% vs $1.25 | $377M+6.4% vs $354M |
Q1 2026 Feb 26, 2026 | $1.67+41.5% vs $1.18 | $407M+10.8% vs $367M |
Q4 2025 Nov 6, 2025 | $1.27+0.0% vs $1.27 | $384M+4.4% vs $368M |
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price
Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent
Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer
BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to LUTATHERA® (lutetium Lu 177 dotatate).
Benchmark LNTH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Lantheus Holdings, Inc. (LNTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $99.65 | $6.49B | 29.22 | 0.5% | 15.15% | 21.45% | — | |
| $221.15 | $32.08B | — | 9.85% | 26.94% | 23.88% | — | |
| $136.79 | $12.53B | 38.10 | 18.3% | 10.11% | 27.93% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $35.50 | $25.65B | -82.56 | -71.57% | -3534.88% | -5.33% | — | |
| $312.39 | $324.12B | 38.28 | 18.48% | 17.7% | 48.44% | — |
Lantheus Holdings, Inc. (LNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Lantheus Holdings, Inc. (LNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 4, 2026·SEC
Aug 3, 2026·SEC
Get notified when LNTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lantheus Holdings, Inc. (LNTH) stock FAQ — growth, dividends, profitability & financials explained
Lantheus Holdings, Inc. (LNTH) reported $1.56B in revenue for fiscal year 2025. This represents a 440% increase from $288.1M in 2012.
Lantheus Holdings, Inc. (LNTH) grew revenue by 0.5% over the past year. Growth has been modest.
Yes, Lantheus Holdings, Inc. (LNTH) is profitable, generating $275.3M in net income for fiscal year 2025 (15.2% net margin).
Lantheus Holdings, Inc. (LNTH) has a return on equity (ROE) of 21.4%. This is excellent, indicating efficient use of shareholder capital.
Lantheus Holdings, Inc. (LNTH) generated $509.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
